Fatigue in Myeloproliferative Neoplasms: Causes and Mechanisms
Fatigue in MPN is multifactorial, driven primarily by chronic inflammation (elevated IL-1, IL-6, IL-8, TNF-α), disease-related factors (anemia, splenomegaly, constitutional symptoms), and concurrent treatable conditions (depression, sleep disturbance, pain, nutritional deficits, deconditioning). 1
Primary Disease-Related Causes
Inflammatory Cytokine Dysregulation
The most significant contributor to MPN-related fatigue is the overproduction of inflammatory markers resulting from dysregulated signaling pathways and genomic instability inherent to these malignancies. Clear relationships exist between fatigue and specific cytokines, particularly IL-1, IL-6, IL-8, and TNF-α 1. This inflammatory burden distinguishes MPN fatigue from normal tiredness and explains why it persists despite rest.
Hematologic Abnormalities
- Anemia (hemoglobin <10 g/dL) is a major contributor, particularly in primary myelofibrosis where severe anemia often requires frequent transfusions 2
- Splenomegaly causes early satiety, abdominal discomfort, and contributes to poor post-transfusion increments 2
- Advanced disease features correlate with higher fatigue severity 3
Disease Subtype Variations
While fatigue affects all MPN subtypes, the burden varies:
- Primary myelofibrosis: Highest symptom scores and most severe fatigue 4
- Polycythemia vera: 84.9% report fatigue 3
- Essential thrombocythemia: 72.4% report fatigue 3
These rates are significantly higher than published controls (P < 0.0001) 3.
Treatable Contributing Factors
The NCCN guidelines emphasize that all medical and substance-induced treatable contributing factors must be addressed first 5. These include:
Concurrent Symptoms (Symptom Clustering)
Fatigue rarely occurs alone in MPN patients. Assess and treat these commonly clustered symptoms 6:
- Depression and anxiety: Fatigue correlates moderately with depression (r=0.41) 6
- Sleep disturbances: Present in 30-75% of cancer patients; assess for sleep apnea, poor sleep hygiene 6
- Pain: Essential to assess and treat effectively 6
- Pruritus: Reported in 52.2% of MPN patients 3
- Night sweats: Reported in 49.2% 3
Metabolic and Endocrine Factors
Perform laboratory evaluation based on symptom severity 7:
- Complete blood count with differential (compare to baseline hemoglobin/hematocrit)
- Comprehensive metabolic panel (electrolytes, hepatic/renal function)
- Thyroid-stimulating hormone (TSH)
- Consider more comprehensive endocrine evaluation if other symptoms present
Lifestyle and Functional Factors
- Deconditioning: Sedentary lifestyle paradoxically worsens fatigue and drives further cytokine production 1
- Nutritional deficits: Weight/caloric intake changes 7
- Medication side effects: Review sleep aids, pain medications, antiemetics 7
- Alcohol/substance use 7
Comorbidities
Assess for cardiac dysfunction, pulmonary dysfunction, renal dysfunction, arthritis, neuromuscular complications 7.
Age-Related Considerations
Higher age shows significant associations with multiple symptoms 4:
- Brief Fatigue Inventory scores increase with age
- Early satiety, concentration problems, dizziness, insomnia, cough, and weight loss all correlate with older age
Notably, blood values, disease duration, and myelosuppressive treatment do not significantly associate with MPN-SAF symptom scores (except higher hemoglobin correlating with sad mood) 4.
Functional Impact
The burden of fatigue in MPN is substantial 3:
- 80.7% of MPN patients self-report fatigue (highest among all constitutional symptoms)
- 34.5% need assistance with activities of daily living
- 11.2% report MPN-associated medical disability
- Majority experience restricted participation in social functions and physical activity
Assessment Framework
Use the MPN Symptom Assessment Form (MPN-SAF) at baseline and monitor during treatment 5. The MPN-SAF Total Symptom Score rates fatigue from 0 (absent) to 10 (worst imaginable) over the past 24 hours 5.
Key distinction: MPN-related fatigue is "a distressing, persistent, subjective sense of tiredness or exhaustion related to cancer or cancer treatments that is disproportional to recent activity and interferes with usual functioning" 8. Unlike normal fatigue, it is not ameliorated by rest 8.